Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too have the available treatment options. Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic ther...
Saved in:
| Published in: | Journal of the European Academy of Dermatology and Venereology Vol. 32; no. 7; pp. 1111 - 1119 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
John Wiley and Sons Inc
01-07-2018
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Insights into the pathophysiology of autoimmune inflammatory diseases including psoriasis have advanced considerably in recent years, and in parallel, so too have the available treatment options. Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis factor‐alpha (TNF‐α) inhibitors and later, agents targeting interleukin (IL)‐12/23 and IL‐17. The most recent evidence suggests that IL‐23 might be an even more potent target for the effective treatment of psoriasis and other autoimmune inflammatory disorders. This review will describe recent developments leading to the current understanding of the key role of IL‐23 as a ‘master regulator’ of autoimmune inflammation and the clinical evidence for agents that specifically target this modulator in the context of treating psoriasis, spondyloarthropathy and inflammatory bowel disease. |
|---|---|
| Bibliography: | Disclosures Funding sources : M.J.G. was an advisory board member, principal investigator, speaker and/or consultant for Abbvie Inc., Actelion Pharmaceuticals, Akros Pharma Inc., AMGEN Inc., Boehringer Ingelheim International GmbH, Bristol‐Myers Squibb Company, Celgene Corporation, Dermira Inc., Eli Lilly and Company, Galderma SA, GlaxoSmithKleine, Janssen Inc., LEO Pharma, MedImmune, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Laboratories, Sanofi Genzyme, UCB, and Valeant Pharmaceuticals Inc. K.A.P. was a consultant, speaker, scientific officer, advisory board or steering committee member and/or received clinical research grants or honoraria from AbbVie, Akros, Allergan, Amgen, Anacor, Astellas, AstraZeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol‐Myers Squibb, CanFite, Celgene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genetech, GSK, Janssen, Kyowa Hakko Kirin, Leo, MedImmune, Meiji Seika Pharma, Merck (MSD), Merck‐Serono, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi‐Aventis/Genzyme, Takeda, UCB, and Valeant. C.W.L. was a consultant, speaker, principal investigator and/or received honoraria from Abbvie, Amgen, Boehringer, Eli Lilly, GSK, Janssen, LeoPharma, Merck, Novartis, Takeda, and Valeant. Janssen Inc. funded this work and provided formal review of the manuscript. Funding was also provided to Ardeane Healthcare Solutions for assistance with manuscript preparation and editing, and for artwork. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ISSN: | 0926-9959 1468-3083 |
| DOI: | 10.1111/jdv.14868 |